SS-31 Research for Age-Related Macular Degeneration
An evidence-based overview of research examining SS-31 in the context of age-related macular degeneration. This page synthesizes findings from peer-reviewed literature.
Research Summary
The open-label Phase 1 ReCLAIM study (NCT02848313) reported improvement in low-luminance visual acuity in intermediate dry AMD patients. The randomized Phase 2 ReCLAIM-2 trial (NCT03891875, n=176), evaluating effect on geographic atrophy progression, completed in 2022. A Phase 3 dry AMD trial, ReNEW (NCT06373731), is ongoing with primary completion expected in 2027.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. SS-31 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.